Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial

Heart and Vessels

Volumn 30, Issue 3, 2015, Pages 286-295

  Christoph, Marian ^a   Herold, Joerg ^b   Berg Holldack, Anna ^a   Rauwolf, Thomas ^b   Ziemssen, Tjalf ^c   Schmeisser, Alexander ^b   Weinert, Sönke ^b   Ebner, Bernd ^a   Said, Samir ^b   Strasser, Ruth H ^a   Braun Dullaeus, Ruediger C ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Atherosclerotic plaque progression, atherosclerotic plaque composition; Cardiovascular disease; Intravascular ultrasonography; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARDIOVASCULAR AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ACUTE CORONARY SYNDROME; AGED; AGONISTS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DEVICES; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; ECHOGRAPHY; FEMALE; GERMANY; HUMAN; INTERVENTIONAL ULTRASONOGRAPHY; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STENT; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NECROSIS; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84893431631     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0480-0     Document Type: Article

References (34)

1. Virmani R, Burke AP, Farb A, Kolodgie FD (2006) Pathology of the vulnerable plaque. J Am Coll Cardiol 47:C13–C18
2. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364:226–235
3. Garcia-Garcia HM, Costa MA, Serruys PW (2010) Imaging of coronary atherosclerosis: intravascular ultrasound. Eur Heart J 31:2456–2469
4. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J (1993) Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69:377–381
5. de Graaf MA, van Velzen JE, de Graaf FR, Schuijf JD, Dijkstra J, Bax JJ, Reiber JH, Schalij MJ, van der Wall EE, Jukema JW (2013) The maximum necrotic core area is most often located proximally to the site of most severe narrowing: a virtual histology intravascular ultrasound study. Heart Vessels 28:166–172
6. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365:2078–2087
7. Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hirano T, Hibi K, Terashima M, Michishita I (2013) Impacts of age on coronary atherosclerosis and vascular response to statin therapy. Heart Vessels. doi:10.1007/s00380-013-0387-1
8. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE (2010) Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 55:2736–2742
9. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106–1118
10. Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T, Echizen T, Sasaki S, Hanada H, Osanai T, Okumura K (2007) Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22:146–151
11. Pfutzner A, Marx N, Lubben G, Langenfeld M, Walcher D, Konrad T, Forst T (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925–1931
12. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokáň M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Škrha J, Smith U, Tatoň J (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
13. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561–1573
14. Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, Sawada T, Kawamori H, Kato H, Miyoshi N, Hirata K (2009) Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 73:343–351
15. Mehta SK, McCrary JR, Frutkin AD, Dolla WJ, Marso SP (2007) Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque. Eur Heart J 28:1283–1288
16. Rodriguez-Granillo GA, Serruys PW, McFadden EP, van Mieghem CA, Goedhart D, Bruining N, van der Steen AF, van der Giessen WJ, de Jaegere P, Vince DG, Sianos G, Kaplow J, Zalewski A, de Feyter PJ (2005) First-in-man prospective evaluation of temporal changes in coronary plaque composition by in vivo intravascular ultrasound radiofrequency data analysis: an Integrated Biomarker and Imaging Study (IBIS) substudy. EuroIntervention 1:282–288
17. Waxman S, Ishibashi F, Muller JE (2006) Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 114:2390–2411
18. Philipp S, Bose D, Wijns W, Marso SP, Schwartz RS, Konig A, Lerman A, Garcia-Garcia HM, Serruys PW, Erbel R (2009) Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. Eur Heart J 31:196–202
19. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW (2010) Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 121:1176–1187
20. Rodriguez-Granillo GA, García-García HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, Serruys PW (2005) In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 46:2038–2042
21. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE (2010) Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 55:2399–2407
22. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG (2002) Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106:2200–2206
23. Kubo T, Maehara A, Mintz GS, Doi H, Tsujita K, Choi S-Y, Katoh O, Nasu K, Koenig A, Pieper M, Rogers JH, Wijns W, Böse D, Margolis MP, Moses JW, Stone GW, Leon MB (2010) The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization. J Am Coll Cardiol 55:1590–1597
24. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108:1664–1672
25. Hartmann M, Mattern ES, Huisman J, van Houwelingen GK, de Man FH, Stoel MG, Danse PW, Louwerenburg HW, von Birgelen C (2009) Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo. Int J Cardiovasc Imaging 25:13–23
26. Nair A, Margolis MP, Kuban BD, Vince DG (2007) Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention 3:113–120
27. Rodriguez-Granillo GA, Vaina S, Garcia-Garcia HM, Valgimigli M, Duckers E, van Geuns RJ, Regar E, van der Giessen WJ, Bressers M, Goedhart D, Morel MA, de Feyter PJ, Serruys PW (2006) Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. Int J Cardiovasc Imaging 22:621–631
28. Marx N, Wohrle J, Nusser T, Walcher D, Rinker A, Hombach V, Koenig W, Hoher M (2005) Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112:2792–2798
29. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J (2003) Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:E5
30. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547–1554
31. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572–2581
32. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493–2499
33. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, Driva M, Hahalis G, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW (2013) Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 61:1679–1685
34. Govindan J, Evans M (2012) Pioglitazone in clinical practice: where are we now? Diabetes Ther 3:1–8